04.28.25 -- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers

Explore our ddPCR method for assessing plasmid-derived antibiotic resistance gene impurities in rAAV products to enhance regulatory compliance and ensure the safety and quality of gene therapy vectors.

This study aims to identify the cause of AAV9 potency loss observed during short-term storage at elevated temperatures and long-term refrigeration.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Low AAV yields and absent platform processes raise production costs—discover a scalable suspension-based solution.

Partnering with an experienced CDMO early can ease funding challenges and secure clinical material for AAV research.

Explore specificities and challenges, leveraging automation for scalability with the Cocoon^® Platform, and building a vein-to-vein network to achieve ‘just-in-time’ delivery of therapies.

Oncolytic viruses have the potential to revolutionize standard cancer treatment, but their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up.